AbbVie Inc. is 142.9x more valuable than Arcus Biosciences, Inc. by market capitalization ($397.44 B vs $2.78 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RCUS | ABBV |
|---|---|---|
| Market cap | $2.78 B | $397.44 B |
| US-listed rank | #1869 | #28 |
| Revenue (latest FY) | $247.00M | $61.16B |
| Net income (latest FY) | -$353.00M | $4.23B |
| Net margin | -142.9% | 6.9% |
| P/E (trailing FY) | - | 94.0 |
| SEC filings | 567 | 1,008 |
AbbVie Inc. is 142.9x more valuable than Arcus Biosciences, Inc. by market capitalization ($397.44 B vs $2.78 B).
In their latest fiscal years, Arcus Biosciences, Inc. reported $247.00M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Arcus Biosciences, Inc. and AbbVie Inc., or browse the full rankings.